1. JNJ can not buy something not proven.
2. No Expenses for ACHN to run Phase3 and Approvals
3. Mkting Expenses = $0 and JNJ can give tough competition to everyone out there worldwide including GILD
4. Royalties Hansome in Millions.
5. Now ACHN concentrate for D-factor Inhibitors and compete with VRTX
ust as contrarians would have predicted, the biggest rally of the last couple of years — during the summer of 2013 — came in the wake of the greatest amount of bearishness (when the HGNSI dropped to minus 56.7%). Contrarian analysis leads us to expect that it will take a similar amount of bearishness to catalyze a rally of similar magnitude to what was experienced then.
Achillion Achieves 100% SVR12 in Phase 2 Trial Evaluating 6-Week Combination Treatment With ACH-3102
- Achillion achieves 100% SVR12 in six-week regimen with combination of ACH-3102 and sofosbuvir for treatment-naïve genotype 1 HCV -
- Achillion to initiate 4-week treatment regimens based on the strength of ACH-3102 antiviral data -
NEW HAVEN, Conn., Feb. 9, 2015 (GLOBE NEWSWIRE) --Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced updated interim results from the ongoing interferon-free, ribavirin-free, Phase 2 study to evaluate the efficacy, safety, and tolerability of six weeks of 50 mg of ACH-3102 and 400 mg of sofosbuvir, a marketed nucleotide polymerase inhibitor, in treatment-naïve genotype 1 HCV-infected patients. The primary objective of the study is determination of sustained viral response 12 weeks (SVR12) after completion of therapy. One hundred percent of patients (12/12) in the six-week treatment duration arm achieved SVR12, which included patients with high baseline viral load.
"The ability to further shorten treatment duration to only six weeks and maintain excellent SVR12 rates remains the goal for clinicians and patients, and I am pleased that these Phase 2 results support that goal. The profile of ACH-3102, represents an important and exciting treatment option to shorten treatment duration for patients infected with HCV," commented Professor Edward Gane, M.D., Deputy Director and Hepatologist, New Zealand Liver Transplant Unit, Auckland City Hospital in New Zealand, and Lead Investigator in the Phase 2 study of ACH-3102 and sofosbuvir and the ACH-3422 nucleotide inhibitor program.
Dr. Milind Deshpande, President and Chief Executive Officer of Achillion, commented, "Our goal is to deliver short duration, widely accessible treatments to all HCV patients. We believe that these results with ACH-3102 represent the shortest duration and highest response achieved to date with any two-drug, direct-acting antiviral regimen for HCV. Given the exceptional profile of ACH-3102, we will now be evaluating four- and six-week treatment durations that leverage all of our HCV assets including ACH-3102, ACH-3422, and sovaprevir."
A key objective of the collaboration will be to develop a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of HCV. An initial regimen that is planned to be explored will feature Achillion's ACH-3102, an NS5A inhibitor currently in Phase 2 clinical studies that has been granted Fast Track designation by the U.S. Food and Drug Administration, in combination with an NS3/4A HCV protease inhibitor plus an NS5B HCV polymerase inhibitor from the collaboration.
SPARTA Phase 2 program which evaluated 6 weeks durations with once-daily regimens of ACH-3102 and ACH-3422, with or without sovaprevir, for treatment naïve genotype 1 HCV patients. Meaning sofosbuvir-sparing regimens that will leverage shorter durations of sofosbuvir in combination with ACH-3102 is already evaluated for 4 weeks regimen, and data shall be anytime soon.
Yesterdays better Jobs growth is a Lie ! Nobody can verify those figures......GOLD will rise to $1400 or More...
Goldcorp Inc. (TSX:G)(NYSE:GG) isn’t usually the first name that comes to mind when investors start looking for dividend stocks.
The gold miner is normally picked as a way to play a rise in precious metals prices, but the company also pays a monthly distribution that currently offers shareholders a 3% yield.
Let’s take a look at Goldcorp to see if it should be in your portfolio.
Goldcorp actually has a solid history of dividend growth. In the past five years the annualized distribution has more than tripled from US$0.18 per share to the current payout US$0.60 per share.
The company reiterated its 2015 gold guidance, raised it for copper and trimmed its capex. "Gold guidance of 6.2-6.6Moz, cash costs of $600-$640/oz and AISC of $860-$895/oz were reiterated. Copper guidance increased to 480-520Mlbs from 310-340Mlbs on Lumwana's continuation. ABX trimmed $0.1B from capex, with $0.2B in savings offset by +$0.1B at Lumwana," the analysts wrote.
Barrick Gold also reiterated its debt reduction target besides announcing the initiation of the Zaldivar sale partial divestiture process.
The EPS estimates for 2015, 2016 and 2017 were raised from $0.41 to $0.47, from $0.64 to $0.66 and from $0.42 to $0.47, respectively, to reflect lower DD&A expenses.
ACHN would be more than GILD once 4 weeks report is Out!!
Listen Basher ! How much Short R U? Get your pants up as SEC filling underway. More details of the deal is in the filling. From face value of this collaboration even $20 is not enough as GILD enjoying $12.5Billions in this Market which JNJ+ACHN can dominate with Triplet nuke short term treatment.
JNJ ...Zytiga is the example when DNDN was ruling the Prostate Cancer Market like GILD today. By the way you know probably that DNDN was darling of WallStreet which now bankrupted.